How to Source Desvenlafaxine Extended-Release Tablets for Pharmaceutical Formulation

Desvenlafaxine Extended-Release Tablets (Extended-Release Tablets, 25 mg, 50 mg, 100 mg) is classified under Antipsychotropic Drugs. It is therapeutically aligned with reference brands such as Pristiq®(US & EU), Khedezla®(US). This guide highlights key sourcing factors buyers should consider when procuring high-quality Desvenlafaxine Extended-Release Tablets for formulation, R&D, or bulk manufacturing.

Product Overview: Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that enhances neurotransmitter levels to help regulate mood and emotional balance. It is primarily used for the treatment of major depressive disorder (MDD) in adults. The extended-release formulation ensures once-daily dosing, providing consistent therapeutic effects with improved adherence and reduced dosing frequency.

1. Regulatory Compliance & Documentation

Ensure suppliers provide:

• ✔ Valid DMF (Drug Master File)
• ✔ COA (Certificate of Analysis) for each batch
• ✔ GMP, ISO, or ICH Q7 compliance certificates

2. Purity, Grade & Specification Matching

Desvenlafaxine Extended-Release Tablets must meet exact grade and purity for your dosage form:

• ✔ USP / EP / JP grade verification
• ✔ Particle size distribution check
• ✔ Residual solvent and heavy metal limits

3. Supplier Reliability & Audit History

• ✔ Positive past audit reports
• ✔ Pharma client references
• ✔ Years of proven API manufacturing experience

4. Commercial Terms: Pricing, MOQ & Flexibility

• ✔ Transparent pricing
• ✔ Pilot batch MOQ flexibility
• ✔ Volume-based discounts

5. Lead Time, Inventory & Logistics

Typical lead time for Desvenlafaxine Extended-Release Tablets is 4–6 weeks.

• ✔ Emergency dispatch options
• ✔ Regional warehousing
• ✔ Special storage if needed

6. Formulation Support

• ✔ Technical datasheets
• ✔ Sample availability
• ✔ Stability study support

Conclusion

Sourcing Desvenlafaxine Extended-Release Tablets is more than procurement—it’s a strategic partnership. With its extended-release tablets form and 25 mg, 50 mg, 100 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.

Frequently Asked Questions For Sourcing of Desvenlafaxine Extended-Release Tablets